CollPlant Biotechnologies Ltd.

Welcome to the Coal Plant Biotechnologies Investor Conference call to discuss financial results for the full year and fourth quarter of 2024 and corporate updates. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Doreen. Korowski of LifeSci Advisors. Thank you. Please go ahead.

I would like to welcome everyone to Coal Plant Biotechnology's Financial Results Conference Call to discuss the results for the full year and fourth quarter ended December 31st, 2024, where management will also provide a corporate business update. With us on the call today from Coal Plant are Yahil Tal, Chief Executive Officer of who will provide a brief overview of the company's programs and associated updates, and Iran Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of CoalClan's financial results for the full year and fourth quarter ended December 31, 2024. Both will be available to answer questions on today's call. Before we get started, I would like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of coal plants filings with the Securities and Exchange Commission. These filings can be found at www.sec.gov or on Coal Plant's website at www.coalplant.com. In addition, any forward-looking statements made on this call represent Coal Plant's views only as of today, March 26, 2025, and should not be relied upon as representing the company's views as of any subsequent date. Coal Plant Management specifically disclaims any obligation to update or revise any of these forward-looking statements. Finally, coal plant management will refer to certain financial measures not reported in accordance with GAAP on this call. You can find reconciliations of these non-GAAP financial measures to the GAAP financial measures in the earnings press release that Coal Plant published earlier today, and which is available on Coal Plant's website at ir.coalplant.com. Now let me turn the call over to Yahil Ta, Chief Executive Officer of Coal Plant Biotechnologies. Please go ahead, sir.

Good morning, everyone, and thank you for joining us today on Cold Plants Investor Conference Call to discuss our fourth quarter and full year 2024 financial results and corporate development as we pursue our mission to be a leader in regenerative medicine. You may have seen that the field of regenerative medicine was highlighted at the end of the last year when the first lab-grown blood vessels were approved by FDA for use by surgeons to restore blood flow in patients with traumatic injuries or in patients who need coronary bypass. This approval is a major milestone for the sector, a research and development effort that has finally been able to translate from an exciting bedside idea to an actual FDA-approved product. As such, we want to emphasize our own proprietary programs in regenerative medicine and regenerative aesthetics and that we are advancing these programs ourselves through preclinical and clinical studies and ultimately potential collaborative agreements. The advancement of our Wally-owned programs represent an additional opportunity for long-term value creation for our stakeholders at Cold Plants. Therefore, I would like to start with highlighting our photocurable dermal filler candidate, which is in the preclinical phase. The photocurable dermal filler is our own, and the market it is intended for is valued approximately $6.3 billion, and with compound annual growth rate of 10%. We have received very positive feedback from talk leaders in the field of aesthetic medicine related to the experimental use of the photocurable dermal filler. Highlights from these testimonials mention that it could be a game changer for facial plastic surgery and the soft tissue filler, as well as huge advance in the dermal and soft tissue market. and for facial plastic surgery, and that nothing like this is observed with available fillers with the potential to change the overall approach of long-lasting facial sculpting. Full video testimonials from each physician can be found within our corporate presentation on our website. In addition to our proprietary photocurable dermal filler in development, our collaboration with AbbVie is focused on the development of another dermal and soft tissue filler product for the medical aesthetics market. In February 2025, Cold Plant announced that AbbVie is collecting data and conducting a review of the results from the first cohort of patients enrolled in the dermal and soft tissue filler clinical trials initiated in 2023. Next steps for the program are to be determined upon complete assessment. In addition, following a development achievement, Corplant received a $2 million payment from Avli. Now, on to our second proprietary program in regenerative medicine, our regenerative breast implants. This quarter, we continue to advance the preclinical testing of our commercial-sized breast implants, now 250 in volume. This study now, using these commercial-sized prototypes, is critical to advancing our technology towards a marketed product and creating significant shareholder value. In August 2024, Kotland launched this preclinical study with two arms, where the surgical protocol was refined to include implantation through small incision while preventing implant displacement or inversion. We were able to accomplish this with enhanced, more durable form of the implant that we were able to produce. Analysis of MRI and ultrasound data conducted early this year confirmed visual integration and vascularization, offering valuable diagnostic tools for future clinical applications. At six months post-implantation, one study arm has shown promising outcomes with the implant demonstrating vascularization and rapid tissue ingrowth within the clinical-sized implant. No complications such as capsule formation, calcifications, and local tissue reactions were observed. Additionally, volume retention and mechanical properties were maintained in the successful study arms. Following this study, Colplant will continue to optimize the regenerative breast implants to ensure longevity and remodeling of the nail tissue with the goal of readying the implants to enter the clinic. Our regenerative breast implant product candidate would be revolutionary for both women undergoing aesthetic enhancement as well as cancer patients undergoing breast reconstruction. since it has the potential to overcome the challenges of existing breast implants made of silicone, saline, or autologous fat tissue. Our recombinant human collagen technology, which is the backbone of our product candidate pipeline and commercial products, is the most characterized collagen on the market today, including its molecular, biological, and physical properties. There is continuous demand for our bioinks, and other applications for recombinant human collagen. Along these lines, we have had additional interest from a wide range of companies that want to gain access to our RH collagen and are engaged in discussions. That concludes my initial remarks. Now I will turn the call over to our Deputy CEO and Chief Financial Officer, Eran Wotem, to provide a recap of the financial results.